MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer

NCT06840665 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Rectal Cancer

Interventions

DRUG: PD-1 antibody
DRUG: Oxaliplatin
DRUG: Capecitabine

Sponsor

Fudan University